Navigation Links
Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
Date:12/10/2007

irectors and executive officers of Regeneration Technologies and their ownership of Regeneration Technologies common stock is set forth in the proxy statement, dated March 30, 2007, for Regeneration Technologies' annual meeting of stockholders, as filed with the S.E.C. on a Schedule 14A. Information about the directors and executive officers of Tutogen and their ownership of Tutogen common stock is set forth in the proxy statement, dated February 5, 2007, for Tutogen's annual meeting of stockholders, as filed with the S.E.C. on a Schedule 14A. Additional information regarding the interests of those participants and other persons who may be deemed participants in the merger may be obtained by reading the joint proxy statement/prospectus regarding the proposed merger when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

Financial Tables to Follow

Consolidated Statement of Income (Loss)

Years Ended September 30, 2007, 2006 and 2005

(In Thousands, Except for Share and Per Share Data)

2007 2006 2005

Revenue $53,819 $37,947 $31,860

Cost of revenue 23,009 16,336 20,129

Gross profit 30,810 21,611 11,731

Operating Expenses

General and administrative 9,277 7,803 5,790

Distribution and marketing 15,795 12,261 11,509

Research and development 2,203 1,834 1,659

Total Operating Expenses 27,275 21,898 18,958

Operating income (loss) 3,535 (287) (7,227)

Foreign exchange loss (118) (311) (173)

Interest and
'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 5 BioSpecifics,Technologies Corp. (OTC Bulletin Board: BSTC), ... products, announced today that,it has signed an agreement ... future royalty obligations for Peyronie,s disease by buying ... payment., BioSpecifics has modified its previously announced ...
... to Expand Business Development Efforts, SALT LAKE ... company,focused on the development of molecular diagnostic and ... today that Joe Ross has,joined the executive management ... Initiatives., In this new role, Ross will ...
... BFRM ) today announced its financial results for the ... sales were $16.7,million for the quarter ended June 30, 2008 ... 2007, an increase of $1.3 million or 8.4%.,The net loss ... as,compared to a net loss of $4.9 million for the ...
Cached Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Axial Biotech appoints new Vice President of Strategic Initiatives 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 3BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 5BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 6BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 7BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 8BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 9
(Date:6/24/2015)... This report provides market analysis of the ... It contains an analysis of the drivers, challenges, and ... from the short, medium, and long term perspective landscapes. ... and technology trends that currently, prevail in the market. ... to efficiently manage the increasing marine traffic and increasing ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... 2015   MedNet Solutions , an innovative ... spectrum of clinical research, is pleased to announce ... the company,s intuitive, flexible and affordable cloud-based eClinical ... Stevie® Award by the American Business Awards ... category.  The American Business Awards are considered the ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... [TORONTO,Canada, Feb 18, 2014] A protein that has been ... within the cell also plays a direct role in regulating ... the journal Science Signaling (February 18, 2014). ... cells. When these functions are disturbed, diseases such as ...
... Professor of Entomology at North Carolina State University (NCSU), ... lecture at Entomology 2014, the 62nd Annual Meeting of ... in Portland, Oregon, November 16-19, 2014. The topic ... L. Rabb, a professor of entomology at NCSU and ...
... the Department of Energy,s (DOE,s) Office of Science and its ... at the 2014 AAAS Annual Meeting,CHICAGO Attendees of the ... which representatives from DOE,s Office of Science and its labs ... is below: President,s Address ...
Cached Biology News:A role of glucose tolerance could make the adaptor protein p66Shc a new target for cancer and diabetes 2NCSU entomologist Fred Gould to present 2014 Founders' Memorial Lecture 2Department of Energy speakers and sessions at AAAS 2Department of Energy speakers and sessions at AAAS 3Department of Energy speakers and sessions at AAAS 4Department of Energy speakers and sessions at AAAS 5Department of Energy speakers and sessions at AAAS 6
...
... depletion cocktail is tailored to ... from suspensions of non-human primate ... separated using the StemSep compatible ... system. The CD4+ T cell ...
... PW is an intelligent full microplate washer with ... simultaneously. This instrument gives you the best of ... efficiency , Performance ,Separate wash ... wash efficiency. A dispense precision of better than ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: